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 Introduction
 The medical prescription of diacetylmorphine (hero-
in) was the exotic element of the new Swiss drug policy of 
1991 and still is probably one of the most controversial 
practices in clinical medicine despite its documented ef-
fectiveness. Following the Swiss prospective naturalistic 
cohort study which demonstrated feasibility, safety and 
cost-effectiveness  [1–4] , a number of randomised con-
trolled trials in other countries confirmed the role of pre-
scribed diacetylmorphine as an effective therapeutic 
agent  [2, 5–7] . Although these trials differed in design and 
outcome criteria, they all had in common the entry crite-
ria (heroin addicts for whom other treatment including 
methadone maintenance had failed) and the program 
characteristics (supervised injections in the framework of 
a comprehensive assessment and treatment programme). 
A Cochrane review of 8 randomised controlled trials con-
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 Abstract
 Aims: The aim of this paper is to illustrate how Switzerland 
was able to play such a pioneering role in the field of addic-
tion treatment, in creating a drug policy that includes the 
medical prescription of diacetylmorphine (heroin). The pa-
per will also describe the role of knowledge brokering pro-
cesses and coalition building in the different phases of the 
development of the Swiss drug policy.  Discussion: The med-
ical prescription of diacetylmorphine was the exotic element 
of the Swiss drug policy of 1991 and probably still is one of 
the most controversial practices in clinical medicine despite 
its documented effectiveness. Coalitions of change actors, 
across stakeholder groups from many professions and politi-
cians on various levels, succeeded in formulating and start-
ing initiatives for a new drug policy and its innovations. 
Clear, shared objectives and a common feeling of urgency 
brought the coalitions together.  Conclusion: In the case of 
Switzerland, the Confederation took a leading role by facili-
tating communication, encouraging scientific knowledge 
and bringing the various stakeholders on a platform to de-
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cluded: ‘The available evidence suggests an added value 
of heroin prescribed alongside flexible doses of metha-
done for long-term, treatment-refractory, opioid users, to 
reach a decrease in the use of illicit substances, involve-
ment in criminal activity and incarceration, a possible re-
duction in mortality; and an increase in retention in treat-
ment’  [8] . Research evidence, clinical experience and pol-
icy aspects have been presented in an insight publication 
by the European Monitoring Centre for Drugs and Drug 
Addiction EMCDDA  [9] .
 An essential difference in design and terminology oc-
curred during the entire process. The Swiss project at first 
was conceived as a scientific experiment; feasibility, safe-
ty and efficacy were to be tested. The original design was 
a randomised controlled clinical trial with three arms (in-
jectable heroin vs. injectable morphine and injectable 
methadone  [10] ). Therefore, the experiment was named 
PROVE (‘Projekt zur ärztlichen Verschreibung von 
Betäubungsmitteln’, project on medical prescription of 
narcotics). However, problems with intravenous mor-
phine and methadone became obvious very soon and had 
to be stopped; the trial was transformed into a naturalistic 
prospective cohort study without controls (except one 
sub-study with a waiting list design  [11] ). The essential 
feature and innovative element was the use of diamor-
phine as a medicine for substituting street heroin. In or-
der to prevent a common misunderstanding, after the ex-
perimental phase, the therapeutic program was renamed 
heroin-assisted treatment HAT (‘heroingestützte Be-
handlung HeGeBe’). In comparison to the long-standing 
British practice to hand out heroin prescriptions to ad-
dicts, the Swiss concept used supervised heroin injections 
as a pharmaceutical tool in the framework of a compre-
hensive assessment and treatment program. This was 
necessary for the target group of previously treatment-
resistant addicts, and the re-naming was necessary for the 
implementation and consolidation phase in order to 
avoid the notion of ‘just handing out heroin’. The new 
term was increasingly used internationally. However, in 
analogy to other agonist maintenance treatments of opi-
oid dependence, the appropriate term used here is heroin 
maintenance treatment.
 Based on the evidence and clinical experience, heroin 
maintenance treatment is by now part of the treatment 
system in 6 countries. However, all this has not led to an 
unanimous acceptance amongst the medical community. 
A wide range of concerns and expected risks for patients, 
for other treatment approaches, for society at large were 
raised from the beginning  [10] and had to be carefully 
examined in the light of outcomes  [12] . Also, ethical ar-
guments are mentioned by opponents and discussed  [13, 
14] .
 The aim of this paper is to illustrate how a basically 
conservative country like Switzerland was able to play 
such a pioneering role in the field of addiction treatment 
and in creating a drug policy which includes the medical 
prescription of heroin, as part of the therapeutic arsenal.
 The paper at hand is not a systematic review based on 
literature search, but a case study including an applica-
tion of selected relevant theoretical models.
 The Paradigm Change in Swiss Drug Policy of 1991
 Unlike other countries of the Organisation for Eco-
nomic Co-operation and Development (OECD), Swit-
zerland does not have a government and an opposition. 
In the executive body, the Federal Council (Bundesrat), 
the four largest parties from the political landscape are 
represented. In 1991, the Federal Council decreed a new 
national drug policy, backed up by a shared policy plat-
form of three major political parties  [15] .
 Before 1991, drug policy was largely determined by the 
Swiss narcotic law, revised in 1975. It was based on strict 
prohibition, even of consumption and preparatory acts 
for personal use. The treatment system diversified during 
the following years, including numerous drug-free thera-
peutic communities and agonist maintenance therapies 
(methadone, later also buprenorphine), but medical and 
social support for illegal injectors was considered to fa-
cilitate the habit. Provision of injection equipment was 
prohibited. This policy could not prevent a steady in-
crease in the incidence and prevalence of drug use, espe-
cially of heroin injecting and its sequelae (increase in 
mortality, in blood-borne infections, in drug-related 
criminality and in drug trafficking). Finally, the misery 
and violence in the open drug scenes in major cities be-
came intolerable, incompatible with the self-image of a 
well-organised society, and a challenge for a radical poli-
cy change. These massive open drug scenes in ‘needle 
parks’ were a result of repeated failure in dissolving drug 
scenes in more vulnerable residential or business areas; 
instead of chasing them around, police profited from ob-
serving and controlling criminal activities in a central lo-
cation.
 The new policy introduced harm reduction as a 4th 
pillar besides prevention, treatment and law enforce-
ment. It also called for innovative approaches in all pil-
lars, including medical prescription of heroin, and for ap-
propriate documentation and evaluation of such innova-
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tions. It did not impose a special action plan, but exposed 
options for innovation, collaboration and evaluation, and 
invited creative answers to the existing or emerging prob-
lems. The following objectives prevailed: to stabilise and, 
in the long term, to reduce the number of persons depen-
dent on hard drugs, and to reduce problems relating to 
the consumption of illicit drugs and the effects of such 
problems on society. In accordance, a number of mea-
sures were implemented by the Federal Office of Public 
Health in order to manage the rising drug problem  [16] .
 On the basis of this new policy, a prospective cohort 
study with medical prescription of heroin could be pre-
pared, implemented and evaluated. It included a number 
of clinical and pharmacological sub-studies. When the 
positive outcomes of the study were presented  [4] , en-
dorsed by an international expert committee of World 
Health Organisation  [17] , the Federal Government passed 
an executive order in 1998 as a legal basis to continue 
heroin-assisted treatment for the defined target group. 
Follow-up studies confirmed its feasibility and safety  [1] , 
so that it could be adopted as an additional regular thera-
peutic programme for otherwise treatment-resistant her-
oin addicts, financed by health insurance, and prolonged 
by national parliament in 2003.
 However, opposition to the new policy and especially 
to heroin prescription was raised and led to two initiatives 
for a national referendum. In the Swiss political system, 
referenda must be held if 50,000 citizens request a vote on 
a federal law, or if an initiative to amend the constitution 
is supported by 100,000 signatures collected within 18 
months. In 1993 and 1994, two popular initiatives (refer-
endum requests) were presented, with opposite objec-
tives. The initiative entitled ‘Youth without Drugs’ called 
for a strict, abstinence-oriented drug policy that empha-
sised the role of repression, along with prevention, and 
drug-free therapy. It also was seeking to prohibit medical 
prescription of narcotics. The other initiative entitled ‘For 
a Reasonable Drug Policy’ (‘Droleg’) proposed the oppo-
site, namely, the decriminalisation of drug use, and culti-
vation of plants used to produce drugs, as well as legal 
possession and purchase of drugs for personal use. Fur-
thermore, it implied that the state supervise cultivation, 
import, and production of narcotics and, thereby, make 
trade in narcotics for non-medical purposes possible 
within a defined legal framework providing protection of 
youths and a ban on advertising.
 Both initiatives were rejected by referenda in 1997 and 
1998, respectively, with 70 and 74% of votes. This was un-
derstood as a confirmation of the new national drug pol-
icy.
 When facing the popular initiatives and in order to 
create a legal basis for the new drug policy, an expert 
Commission (the ‘Schild Commission’) was set up in 
February 1996 by the Swiss Federal Department of Home 
Affairs, in view of a revision of narcotic law  [18] . The 
commission’s report put forward several recommenda-
tions, including a continuation of the medical prescrip-
tion of heroin as an additional therapeutic approach, pro-
vided that the good interim results could be confirmed. 
After a formal consultation of the Schild Commission re-
port by the authorities, the majority of cantons, parties, 
and expert organisations expressed acceptance of the 
medical prescription of heroin as an option for therapy 
and harm reduction practice.
 How Can Such a Paradigm Change Be Achieved?
 The Swiss referendum democracy requires a consider-
able degree of citizen engagement and participation. In-
troducing novel approaches for handling sensitive prob-
lems, such as those posed by psychoactive drugs, means 
that the public at large, the voters, need to be well in-
formed and prepared about the issues involved. This, in 
turn, requires a well-organised documented information 
strategy based on synergies between scientific evidence 
and political skills. In order to introduce a new policy, 
therefore, a lengthy consensus-forming process is needed 
and, at the end of the process, citizens are entitled to ac-
cept or turn down parliamentary decisions. This specific-
ity of Swiss politics enhances networking, coalition build-
ing and knowledge brokering activities at various levels 
(community, decision-makers and numerous stakehold-
ers) in the policy process.
 Social science has developed various theoretical con-
cepts for a better understanding of such processes. They 
provide a framework for understanding how societal and 
political resistance against major innovations with un-
known consequences may be overcome. Two types of 
theories will be considered here: on knowledge brokering, 
and on coalition building.
 Knowledge Brokering 
 The theory and practice of knowledge management, 
knowledge transfer and knowledge brokerage is an 
emerging field and has been deployed for some time by 
organisations such as the Canadian Health Services Re-
search Foundation  [19–21] . Knowledge brokering is one 
of the human forces behind knowledge transfer. It is a 
dynamic activity that goes well beyond the standard no-
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tion of transfer as a collection of activities that helps move 
information from a source to a recipient.
 Brokering focuses on identifying and bringing togeth-
er people interested in an issue in order to develop evi-
dence-based solutions. It helps build relationships and 
networks for sharing existing research and ideas and 
stimulating new solutions. Knowledge brokering is then 
a process supporting evidence-based decision-making by 
encouraging the connections that ease knowledge trans-
fer. The process may benefit from a supportive organisa-
tion able to allow a collaborative environment and suffi-
cient resources for the job, processes.
 The characteristics of knowledge brokering are  [21] :
 – Organizing and managing joint forums for policy-
makers and researchers.
 – Building relationships of trust.
 – Setting agendas and common goals.
 – Signalling mutual opportunities.
 – Clarifying information needs.
 – Commissioning syntheses of research of high policy 
relevance.
 – Packaging research syntheses and facilitating access to 
evidence.
 – Strengthening capacity for knowledge translation.
 – Communicating and sharing advice.
 – Monitoring impact on the know-do gap.
 Translating research findings into health policy focus-
es on organizing the interactive process between the pro-
ducers and users of knowledge so that they can co-pro-
duce feasible and policy options based on research issued 
information. The strategy aims to bridge the gaps be-
tween research findings and evidence required in policy-
making.
 Health research and policy-making work in different 
settings, each with their own professional culture, re-
sources and time frames. The communication gap be-
tween these stakeholders is subordinated to the different 
agenda priorities. In the case of the policymaker, there is 
rarely a clear message about the policy challenges; the 
rapid turnover in the political setup focuses on the spe-
cific context to allow for timely and appropriate research 
agendas.
 The research scientist, on the other hand, often pro-
duces scientific evidence not particularly tailor-made to 
be used by the policymaker for the various contexts dur-
ing his period in government.
 Three elements have a major role in enhancing re-
search-policy translation  [22–25] : 
 – Willingness, on the part of the researcher, to justify the 
policy implications of his or her findings.
 – Inclusion of policymakers in negotiating the frame of 
reference before research is undertaken.
 – Trust with an ongoing commitment between research-
ers and policymakers. 
 Coalition Building
 Democratically organised societies have to find ways 
how to proceed when in need of a reformulation of strat-
egies in face of new societal and technological develop-
ments, especially in dealing with controversial preferenc-
es and interests. The area of drug policy adjustment pre-
sents an excellent example for discussing the problem and 
the process of coalition building for finding acceptable 
answers to new challenges.
 Useful network theories and models have focused in-
creasingly on how political, cultural and technological in-
novation and change happens  [26] . A common denomi-
nator of such approaches is a system-based view of socie-
ties, with subsystems and networks of actors initiating 
and supporting innovation, rather than single innovators 
and actors. Well-known examples are the advocacy coali-
tion framework (ACF)  [27] , social network theory  [28] , 
normalisation process theory  [29] , and diffusion of inno-
vations theory  [30, 31] . A more general perspective offers 
the theory of societal learning  [32] .
 A further development is the actor-network theory 
(ANT) which includes non-human factors into the net-
work analysis  [33, 34] . The ANT has been applied, among 
others, to the health field. It is especially interesting for 
analysing drug policy change as it can include epidemio-
logical change as a factor. It has also met substantial crit-
icism; it is argued that research based on ANT perspec-
tives remains descriptive and cannot explain social pro-
cesses. The ANT is more interested in exploring how 
actor-networks get formed, hold themselves together, or 
fall apart.
 Another step was the development of tools for map-
ping out and interpreting scientific controversies in com-
plex matters in order to facilitate orientation and coali-
tion forming  [35] .
 A Process Analysis of Implementing and 
Consolidating the New Drug Policy and Heroin 
Maintenance Treatment
 Both types of theories can be applied to analysing the 
paradigm change described above. The coalition building 
theory is more appropriate for our understanding of the 
preparatory and implementation phases of the process, 
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while knowledge brokerage theory helps to understand 
the consolidation phase.
 Coalition Building in the Early Phases
 The process of re-shaping drug policy was analysed on 
the basis of the ANT and the ACF, in a number of case 
studies in Swiss cities.
 A systematic ANT-based analysis in 4 cities (Bern, 
Chur, St. Gallen, Zurich) built first on the empirical iden-
tification of institutions, actors, competences and proce-
dures which are relevant in the drug policy area was fol-
lowed by an analysis of the specific interaction and de-
pendence patterns. Two separate networks are in focus: 
the policy network and the decision-making network. 
Moving beyond the ANT, specific hypotheses on deter-
minants were tested. As a result, the independent vari-
ables shaping the policy network are the size of the city, 
the size of the local drug problems (including the HIV 
epidemic and the correspondent media interest), the 
dominant political parties and the administrative struc-
ture. On the other side, the decision-making network is 
mainly determined by the structure and characteristics of 
the policy network, and less on the politically and admin-
istratively preferred types of regulatory measures. The 
role of coalition building is well demonstrated  [36] .
 Another analysis was using the ACF, complemented 
by social movement theory and the two concepts of mo-
bilizing structures and political opportunity structures 
 [37–39] . The ACF understands the policy process as a 
competition between coalitions of actors who advocate 
beliefs about policy problems and solutions. In the case of 
Swiss drug policy, this means a competition between a 
prohibitionist and a harm-reduction coalition. The latter 
developed the belief that measures to prevent blood-
borne infections must override the inefficient belief in 
preventing drug use in an abstinence-only perspective – 
not only for the sake of users, but in order to protect the 
general population as well. The implementation of the 
harm reduction policy had to be tailored, in a second step, 
to the needs of public order, reducing public nuisance. 
The concept of ‘Stadtverträglichkeit’ (urban compatibil-
ity) of harm reduction measures was introduced as an 
important additional element.
 Who were the change actors and what were their initia-
tives in the coalition building processes in the city of Zu-
rich? The most diverse organisations and persons started 
to react, at first without a shared action plan, mostly along 
a strategy to avoid specific negative aspects, which in the 
course of action was labelled ‘harm reduction’. The Medi-
cal Association recommended the provision of sterile sy-
ringes and needles, a coalition of infection specialists and 
the Red Cross organised blood testing and hepatitis B im-
munisation right in needle park, ad hoc groups of con-
cerned citizens and parents offered meals, a medical emer-
gency team intervened in innumerable overdose cases, and 
medical, social and psychiatric support was provided in 
easily accessible drop-in centres. A specialised NGO for 
risk-free use of drugs was set up and opened a low-thresh-
old methadone clinic, without obligatory counselling and 
urine controls, but with visual intake control to avoid di-
version and overdose. In 1988, a ‘Drogen Charta’ was set 
up and published by a heterogeneous coalition of politi-
cians, professionals, academics and NGOs. These initia-
tives have been well documented and described  [10, 39, 40] .
 What was the official reaction? After initial rejection, 
low-threshold methadone prescribing was tolerated, as 
well as injection rooms and continued use in shelters. The 
Social Department in the City Administration changed 
from a repressive attitude against rebellious and drug us-
ing youth to an active policy of supporting measures to 
prevent health and social deterioration of users. The City 
Government became an active promoter of prescribing 
heroin to chronic heroin users; this initiative was taken 
up by the Federal Expert Committee on Drugs and final-
ly by Federal Government, in the framework of the na-
tional 4-pillar drug policy of 1991. Harm reduction ap-
proaches were considered to be admissible within the 
framework of national legislation and international con-
ventions by specially mandated law experts.
 The change process described above evolved within 
less than a decade. It was not prepared, not driven by a 
ready-made concept of a new policy or action plan. Nor 
was it based on a consistent concept of an open society 
fostering experimentation and innovation. It was rather 
driven by the unacceptable realities clashing with the 
cherished self-image of professionals in the health and 
social sector of being competent and efficient in meeting 
new demands.
 The ANT certainly applies, on the basis of including 
non-human factors, in this case the excessive drug mar-
kets and the excessive HIV epidemic. As well, the hypoth-
eses of Serduelt  [36] are confirmed. On the other side, the 
ACF theory as applied by Kübler  [39] allows to describe 
the competition between the ‘innovators’ and the opposi-
tion, and it also helps to understand the interaction of 
both these networks in shaping the innovations in order 
to have less unintended negative effects. Finally, the soci-
etal learning theory shows the need how to stabilise the 
process of change in new structural systems as a second-
ary process.
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 Within this overall development, the preparation and 
implementation of heroin maintenance treatment can be 
understood as the result of specific actor networks and 
coalitions. A first proposal for introducing this approach 
was made 1988 in national parliament, but without suc-
cess. André Seidenberg, a general practitioner in Zurich 
city, consulted by many drug users, took up the proposal 
and convinced the head of the social department in the 
city administration; he also implemented the first low-
threshold methadone maintenance clinic. The City Coun-
cil took the proposal to the Federal Council. At the same 
time, the Cantonal Government mandated experts to vis-
it and report on the British practice of heroin prescription 
in its traditional form and in an innovative approach pre-
scribing smokable heroin. The Sub-commission on Drug 
Issues of the Federal Narcotic Commission mandated an 
expert to review all international experience with pre-
scribing narcotics  [41] , and finally mandated another ex-
pert to design a scientific study  [42] . The concept had to 
pass by the Narcotic Commission and the Federal Office 
of Public Health before being submitted to the Federal 
Council. This process included a range of interactions be-
tween medical and law experts, local and national politi-
cians in order to get fine-tuning and growing acceptance 
of the project. It can best be understood as a prominent 
example of the ACF theory.
 Knowledge Brokering in the Consolidating Phase
 Even before the end of the PROVE study, in November 
1994, the Federal Department of Home Affairs gave a 
Commission of experts  [18] the mandate to present a re-
port and recommendations for a revision of the Narcotic 
Law. The Commission held sessions to gather informa-
tion on the state of specialised knowledge, and it organ-
ised hearings on the medical prescription of narcotics and 
on custodial care, which were attended by Swiss and for-
eign experts and other local stakeholders.
 The Commission’s report can be characterised as a 
major effort in knowledge brokering between experts and 
politicians. It pointed out that there were many more 
problems associated with the use of legal products with 
addictive properties (medication, tobacco and alcohol) 
than with the use of illegal drugs. According to the Com-
mission, it was difficult to justify making a distinction 
between legal and illegal drugs, at least from the perspec-
tive of health policy. The recommendations reflected an 
effort to counteract the stigmatisation of the user and to 
give him access to the healthcare delivery system without 
prejudice.
 In detail, the following recommendations were pro-
posed:
 – The Confederation, cantons and communes should be 
required to implement preventive measures. The Con-
federation should also be given a policy coordination 
role with a view to standardise prevention strategies, 
and should adopt the necessary legal measures to en-
sure the funding of information and awareness cam-
paigns.
 – People with drug addiction should have access to in-
stitutions offering harm reduction and coping skill 
programs, so that they can improve their health and 
living conditions. Legal measures should be put in 
place so that the Confederation can require cantons 
and communes to set up such institutions, and coor-
dination should be handled by the Confederation. Fi-
nancial incentives should be offered to the cantons and 
communes.
 – Treatment that meets the specific needs of people with 
drug addiction should be available at in- and out-pa-
tient centres. There should be better cooperation be-
tween the various treatment programs, and drug ad-
diction programs should be better integrated into the 
overall health and social assistance network. The Con-
federation should obtain the powers it requires to co-
ordinate treatment programs, make recommenda-
tions on minimum standards set as benchmarks.
 – HAT trials having yielded positive results and further-
ing scientific confirmation of the research, this novel 
therapeutic approach (targeting a specific group of pa-
tients) should be included in the range of treatments 
offered for addiction disorders. In this event, the Nar-
cotics Act should be amended by removing heroin 
from the list of non-prescribable substances. The Fed-
eral Council should also be given the authority to de-
termine the general conditions applying to such pre-
scriptions.
 – Given the rapid developments and new problems that 
are occurring, the Confederation should strengthen its 
efforts to encourage research in the area of drugs. A 
clear legal framework should be established and, most 
importantly, sufficient funds must be made available. 
The Narcotic Law should include a provision that 
would exempt the Federal Council from complying 
with the legislation under specific general conditions 
in order to authorise trials.
 Another expert committee, the Sub-Commission for 
Drug Issues of the Federal Narcotic Commission, report-
ed that the harm reduction approach was the most suit-
ably adapted model to the Swiss situation which, consid-
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ering the numerous social values and direct democracy, 
required a policy that could integrate different values and 
be sufficiently flexible to react rapidly and effectively to 
change  [43] .
 The Federal Council adopted the proposed recom-
mendations. To give it legal basis, the Federal Council 
proposed a referendum on the issue. National drug policy 
gatherings in 1991 and 1995  [10] provided an impetus to 
involve all the main political and professional actors in an 
intensive debate; the meeting reports opened the debate 
to the media and the general public, which led to a wide-
spread acceptance of the pragmatic policy approach.
 Three major political parties played an important role 
in the processes described here: Liberals (Freisinnig-de-
mokratische Partei), Christian socialists (Christlich-so-
ziale Partei) and Social democrats (Sozialdemokratische 
Partei) formed a joined drug policy platform at national 
level, to support the Federal drug policy issued in 1991. 
Opposition came mainly from the People’s party (Volks-
partei). The same constellation was seen during the refer-
enda. 
 The coalitions supporting harm reduction measures 
were initially only partially the same as the coalitions sup-
porting heroin maintenance treatment. They worked in 
parallel. Later on, they merged when a consolidation of 
the new drug policy was at stake.
 As described under the ‘Schild Commission’, the 
stakeholders in favour of the new policy waited for the 
outcomes of the research project on heroin maintenance 
and planned to use the positive outcomes during the ref-
erenda.
 The role of media for reporting on the process in all 
its phases and aspects should not be underestimated.
Especially before the various national and local referenda 
on the continuation of heroin maintenance treatment, 
extensive reports on expert opinion, on research find-
ings, on public controversies were published in national 
and local papers, and broadcast on radio and television. 
In the Swiss political system with its frequent referenda, 
the knowledge brokering function of the media is indis-
pensable. 
 Conclusions
 Coalitions of change actors across stakeholder groups 
from many professions and politicians on various levels 
succeeded in formulating and starting initiatives for a 
new drug policy and its innovations. Clear shared objec-
tives and a common feeling of urgency brought the coali-
tions together. For the preparation and implementation 
of heroin maintenance treatment, such coalitions and ad-
vocacy networks were indispensable. They will also be in-
evitable for the introduction of other innovations in the 
health field and related areas.
 Brokering initiatives, characterised by a carefully de-
signed process for bringing researchers and policymakers 
together and appropriate institutional embedding, have 
significant impacts on health policy  [24, 25] . In the case 
of Switzerland, the Confederation took a leading role
by facilitating communication, encouraging scientific 
knowledge and bringing the various stakeholders on a 
platform to deliver a consensual political policymaking 
basis. This was facilitated by the Swiss direct democracy 
system, needing a high level of argumentation and a par-
ticipatory approach to implement the new drug policy in 
a highly emotional context. Media had a critical role in 
fostering awareness and opinion shaping in the popula-
tion at large. The result in this case was unequivocal: in 
November 2008, Swiss citizens voted on the 2nd revision 
of the Narcotic Law, which included the heroin mainte-
nance treatment. It was well accepted. 
 In absence of comparable policy analyses from other 
countries such as the Netherlands, Germany, Spain and 
the UK, the Swiss example presented here can only be used 
as an example and starting point for comparative research.
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